1.Li H，Ahonen TJ，Alanen K，et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade［J］. Cancer Res，2004，64（14）：4774-4782.

2.Brooke GN，Parker MG，Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer：differential coactivator recruitment and gene expression［J］. Oncogene，2008，27（21）：2941-2950.

3.Hara T，Miyazaki H，Lee A，et al. Androgen receptor and invasion in prostate cancer［J］. Cancer Res，2008，68（4）：1128-1135.

4.Ricciardelli C，Jackson MW，Choong CS，et al. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential［J］. Prostate，2008，68（8）：830-838.

5.Thomas R，Kim MH. HIF-1 alpha：a key survival factor for serum-deprived prostate cancer cells［J］. Prostate，2008，68（13）：1405-1415.

6.Bray K，Chen H-Y，Karp CM，et al. Bcl-2 modulation to activate apoptosis in prostate cancer［J］. Mol Cancer Res. 2009 Sep；7（9）：1487-1496.

7.Kudahetti S，Fisher G，Ambroisine L，et al. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer［J］. BJU Int，2009，104（1）：20-24.

8.Mao H-L，Zhu Z-Q，Chen CD. The androgen receptor in hormone-refractory prostate cancer［J］. Asian J Androl，2009，11（1）：69-73.

9.Mathew P，Pisters LL，Wood CG，et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer［J］. J Urol，2009，181（1）：81-87；discussion 87.

10.Mazzucchelli R，Barbisan F，Santinelli A，et al. Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer［J］. Int J Immunopathol Pharmacol，2009，22（3）：755-762.

11.Nariculam J，Freeman A，Bott S，et al. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer：the expression of BCL-2，E-cadherin，Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors［J］. Asian J Androl，2009，11（1）：109-118.

12.Ellem SJ，Risbridger GP. Aromatase and regulating the estrogen：androgen ratio in the prostate gland［J］. J Steroid Biochem Mol Biol，2010，118（4-5）：246-251.

13.Fernandez I，Touraine P，Goffin V. Prolactin and human tumourogenesis［J］. J Neuroendocrinol，2010，22（7）：771-777.

14.Fernández-Balsells MM，Murad MH，Lane M，et al. Clinical review 1：Adverse effects of testosterone therapy in adult men：a systematic review and meta-analysis［J］. J Clin Endocrinol Metab，2010，95（6）：2560-2575.

15.Jiang Q，Xia S-J. Zonal differences in prostate diseases［J］. Chin Med J，2012，125（9）：1523-1528.

16.Siegel R，Naishadham D，Jemal A. Cancer statistics，2013［J］. CA Cancer J Clin，2013，63（1）：11-30.

17.Zellweger T，Stürm S，Rey S，et al. Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease［J］. Endocr Relat Cancer，2013，20（3）：403-413.

18.Daniels G，Gellert LL，Melamed J，et al. Decreased expression of stromal estrogen receptor α and β in prostate cancer［J］. Am J Transl Res，2014，6（2）：140-146.

19.Verma V，Sharma V，Singh V，et al. Designed modulation of sex steroid signaling inhibits telomerase activity and proliferation of human prostate cancer cells［J］. Toxicol Appl Pharmacol，2014，280（2）：323-334.

20.刘棚越，周娟，彭御冰，等.正常前列腺间质细胞对前列腺癌细胞糖代谢水平的影响［J］.中华男科学杂志，2015（6）：489-493.

21.Yun H，Xie J，Olumi AF，et al. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells：A prospective therapeutic opportunity［J］. Oncotarget，2015，6（13）：11600-11613.

22.Yang Z，Peng Y-C，Gopalan A，et al. Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer［J］. Dis Model Mech，2017，10（1）：39-52.